The neuropeptide substance P (SP) has wide ranging effects on many cell types. Nilsson et al showed that SP could stimulate connective tissue cell growth by stimulating DNA synthesis in human skin fibroblasts and arterial smooth muscle cells in vitro. 1 Substance P has also been implicated in inflammation owing to its effects on cells associated with acute and chronic inflammatory responses. Substance P promotes chemotaxis of human monocytes, and this appears to be an SP receptor mediated effect as it is blocked by D-amino acid analogues of sp.2 Substance P mediates macrophage activation, including enhancement of the oxidative burst with production of significant amounts of the superoxide anion, hydrogen peroxide, and release of prostaglandin E2, thromboxane B2, and leukotriene C4.3 4 A later event induced by SP is the release of lysosomal enzymes from activated macrophages.4
The neuropeptide substance P (SP) has wide ranging effects on many cell types. Nilsson et al showed that SP could stimulate connective tissue cell growth by stimulating DNA synthesis in human skin fibroblasts and arterial smooth muscle cells in vitro. 1 Substance P has also been implicated in inflammation owing to its effects on cells associated with acute and chronic inflammatory responses. Substance P promotes chemotaxis of human monocytes, and this appears to be an SP receptor mediated effect as it is blocked by D-amino acid analogues of sp.2 Substance P mediates macrophage activation, including enhancement of the oxidative burst with production of significant amounts of the superoxide anion, hydrogen peroxide, and release of prostaglandin E2, thromboxane B2, and leukotriene C4.3 4 A later event induced by SP is the release of lysosomal enzymes from activated macrophages. 4 Direct injection of SP into human skin produces a wheal and flare reaction as seen with histamine, but SP is about 100 times more potent.5 Substance P induces the specific release of histamine from mast cells,6 which will produce vasodilatation, oedema, and an increase in vascular permeability-that is, SP can produce an inflammatory response by a direct or an indirect effect. It is apparent that SP may have a role in inflammation and perhaps is involved in the pathogenesis of inflammatory diseases such as rheumatoid arthritis. This review attempts to tie together past and current ideas about SP and inflammatory arthritis. (a, j, and y preprotachykinin) owing to alternate RNA splicing, and all three can encode for SP. However, a preprotachykinin mRNA can only encode for SP, whereas j3 and y preprotachykinin mRNA can also encode for neurokinin A and other tachykinins. 9 Substance P is widely distributed throughout the central and peripheral nervous systems'0 11 and is synthesised in the cell bodies of peripheral nerves located in the dorsal root ganglia.'2 After synthesis SP is distributed to the central and peripheral nerve terminals by a fast axonal transport system. 13 The rate of transport to the periphery is greater than the transport rate to the central terminals in the spinal cord. 4
In peripheral nerves SP has been localised to small unmyelinated nerve fibres,'5 described as afferent C fibres, and small myelinated fibres (A delta fibres). These fibres are thought to have a nociceptive function-that is, they are only usually stimulated by painful (noxious) stimuli, with neuropeptides such as SP being the central neurotransmitter.'6 As well as this afferent nociceptive role, SP also has an efferent action, where sensory nerve activation causes antidromic (reversed) transmission of nerve impulses (in addition to orthodromic transmission to the spinal cord) in the branches of the same peripheral C fibre (fig 2) . This is known as an axon reflex, and it has been shown that SP is released from sensory nerves after antidromic stimulation. '7 Jansco et 43 Four clinical groups of patients were studied: those with RA, osteoarthritis, Reiter's syndrome, and arthritis following trauma. It was found that apart from the patients with Reiter's syndrome each group had significantly higher concentrations of SP in synovial fluid than were found in paired plasma samples. Concentrations of SP in the group with RA were 946-6 (SEM 82 8) pg/ml in synovial fluid compared with 676-4 (58-1) pg/ml in plasma. This suggested a localised intra-articular source of SP-namely, release from the peripheral C fibres.
It is apparent from the above mentioned studies that detection of SP in human synovial fluid is extremely difficult. Concentrations reported range from 0 to 0 1 [ig/ml (table) . The diversity in results may be due to the inaccuracy of the method used (Chapman and Tsao using high performance liquid chromatography found SP concentrations about 100 times greater than those of Marshall) or a lack of sensitivity of the assay (Devillier et al used an enzyme immunoassay for tachykinin-like immunoreactivity, not specific for SP immunoreactivity. There is the possibility of cross reactivity with neurokinins A and B and SP fragments). Interpretation of the meaning of the concentrations of any substance in synovial fluid poses a problem because, as yet, the production, degradation, and clearance rates of the system have not been elucidated." Substance P receptors If SP has a pathophysiological function in arthritis then it is reasonable to expect altered levels of SP receptors. There are currently three pharmacologically distinct tachykinin receptors -namely, neurokinin 1, 2, and 3. They are defined usually by the rank order of potency of Larsson et al39 40 
Nil
Marshall et al43 946 6 (82 8) tachykinins in binding studies. Substance P has the greatest affinity for the neurokinin 1 receptor but may also interact with neurokinin 2 and 3 receptors, but only at a higher concentration.
It has been shown that the number of receptors for SP/unit area of tissue is increased in inflammatory diseases such as ulcerative colitis.45 This is probably owing to an increase in blood vessel density in the tissue rather than an increase in receptor density. Walsh 
